Finance

Italian drugmaker Chiesi to buy KalVista for $1.9 billion

Published by Global Banking & Finance Review

Posted on April 29, 2026

1 min read

· Last updated: April 29, 2026

Add as preferred source on Google
Italian drugmaker Chiesi to buy KalVista for $1.9 billion

Italian Drugmaker Chiesi to Acquire KalVista for $1.9 Billion

Chiesi's Strategic Expansion in Rare Disease Drugs

Acquisition Details

Deal Overview

April 29 (Reuters) - Italy's Chiesi has agreed to buy KalVista Pharmaceuticals for about $1.9 billion, the company said on Wednesday, as it looks to grow its rare disease drug portfolio.

Reporting and Editorial Information

(Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber)

Key Takeaways

  • The $1.9 billion cash deal underscores Chiesi’s strategic expansion into rare diseases, reinforcing its Global Rare Diseases unit’s growth trajectory (reddit.com)
  • KalVista brings EKTERLY (sebetralstat) — the first and only oral on‑demand therapy for hereditary angioedema — with strong early adoption and revenue of $49.1 million through end‑2025 (kalvista.gcs-web.com)
  • KalVista’s solid commercial execution and cash runway to profitability make it an attractive target, offering Chiesi both innovative pipeline assets and financial stability (kalvista.gcs-web.com)

References

Frequently Asked Questions

Who is acquiring KalVista Pharmaceuticals?
Italian drugmaker Chiesi is acquiring KalVista Pharmaceuticals.
What is the value of the Chiesi and KalVista deal?
The deal is valued at about $1.9 billion.
Why is Chiesi acquiring KalVista Pharmaceuticals?
Chiesi aims to grow its rare disease drug portfolio through this acquisition.
When was the acquisition agreement announced?
The agreement was announced on April 29.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category